Xenleta, a new bacterial pneumonia treatment, is FDA-approved

Drug Info

FDA approves Xenleta to treat bacterial pneumonia

On Monday, the U.S. Food and Drug Administration (FDA) announced its approval of two formulations of Xenleta (lefamulin)—oral and intravenous—to treat community-acquired bacterial pneumonia (CABP) in adults.  Nabriva Therapeutics—a biopharmaceutical company that specializes in the development of anti-infective agents that treat serious infections—developed Xenleta more than 10 years ago. It’s designed for two purposes:  to …

August 20, 2019 •